Hepion Pharmaceuticals files draft information statement for shareholders
HEPA•Draft statement outlines reverse split and share increases
- Hepion shareholder authorization covers a reverse stock split of common stock, with the board able to set a ratio from 1-for-20 to 1-for-50.
- The draft also authorizes an increase in authorized common shares to 750 million from 120 million.
- Equity incentive capacity is set to expand, lifting shares issuable under the 2023 Omnibus Equity Incentive Plan to 18 million from 8 million.
